Abstract
The field of hepatic oncology is rapidly changing due to the availability of a large diagnostic and therapeutic armamentarium. The popularization of several loco-regional treatments LRT) and the recent introduction in clinical practice of drugs such as tyrokinase inhibitors have changed the therapeutic algorithm of hepatocellular cancer (HCC). The role of surgery has been reduced markedly [1, 2]. This editorial aims at reminding surgical as well as medical communities that cure of liver cancer can only be obtained when resecting the tumor appropriately and that (long-term) results can be further improved when adhering to the classical oncologic paradigms.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
